News Hub | News Direct

Healthcare

Addiction Biotech Cannabis Genetics Healthcare Medical Devices Pharmaceutical Science Veterinary
Article thumbnail News Release

Arecor Therapeutics reports strong 2023 results and outlines expanding product pipeline

Arecor Therapeutics PLC

Arecor Therapeutics PLC (AIM:AREC)C CEO Sarah Howell discusses the company's 2023 performance and future plans with Proactive's Stephen Gunnion. Howell highlighted that Arecor has seen significant growth, particularly with the launch of products incorporating its Arestat technology under a global licensing agreement, generating royalties. Six new technology partnerships were established with major pharma and biotech companies, offering potential for future licensing and market development. Arecor focuses on diabetes and obesity, with clinical results for their proprietary product, AT278, expected soon. This highly concentrated, rapid-acting insulin aims to provide better glucose control for type 2 diabetics with high BMI and support the next generation of insulin pump devices. Tetris Pharma, a subsidiary, has shown strong growth under new leadership, with product sales tripling to £2.9 million in 2023. Its lead product, glucagon, has contributed significantly to this growth. Howell also noted the importance of technology partnerships and licensing programs. Arecor has entered into three active license programs and is progressing well with its partners. One notable partnership is with Medtronic to develop a concentrated, stable insulin for intra-peritoneal delivery, aiming to reduce hospital visits for patients with brittle diabetes. Contact Details Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com

May 17, 2024 03:20 AM Eastern Daylight Time

Video
Article thumbnail News Release

Immunic highlights IMU-856 gastrointestinal candidate to mark International Celiac Day

Immunic Inc

Immunic Inc (NASDAQ:IMUX) chief scientific officer Hella Kohlhof joined Proactive's Stephen Gunnion on International Celiac Day, in the middle of Celiac Disease Awareness Month, to discuss the disease and the company’s developments in treating it. Kohlhof explained that celiac disease is a severe autoimmune disorder affecting around 1% of the global population, predominantly females. Unlike gluten intolerance, celiac disease involves an immune reaction to gluten, leading to gut inflammation and destruction. The only current treatment is a gluten-free diet, which is not effective for all patients. Kohlhof elaborated on the disease's scientific background, highlighting its genetic association with specific HLA genotypes (HLA-DQ2 and HLA-DQ8). She explained that celiac disease is triggered by the immune system's reaction to deaminated gluten peptides, causing inflammation and damage to the gut lining. Immunic is developing IMU-856, an epigenetic modulator, to treat gastrointestinal diseases like celiac disease. IMU-856 enhances gut regeneration and strengthens the gut barrier, improving patients' conditions. Kohlhof detailed the successful completion of a Phase 1b study in celiac patients, which demonstrated the drug’s safety, good pharmacokinetic properties, and positive effects on symptoms, biomarkers, gut histology, and nutrient uptake during a gluten challenge. The study confirmed the potential of IMU-856 in treating celiac disease, and further exploration of its mode of action is ongoing. Contact Details Proactive North America +1 604-688-8158 NA-editorial@proactiveinvestors.com

May 16, 2024 05:54 PM Eastern Daylight Time

Video
Article thumbnail News Release

The HERizon Disposable Hysteroscope aims to redefine industry standards

Minerva Surgical, Inc.

Minerva Surgical announces the immediate and exclusive distribution of a new disposable hysteroscope that will be displayed at the Annual Clinical & Scientific Meeting of American College of Obstetricians and Gynecologists in San Francisco, CA. The company plans to soon rebrand the new disposable hysteroscope as HER izon, and their goal is to redefine the standards of efficiency and accessibility in gynecological care. “This marks a significant milestone in the company’s mission to address the needs of gynecologists and further advance Women’s Health,” states Minerva Surgical Chief Medical Officer Eugene Skalnyi, M.D. “ HER izon embodies versatility as a hysteroscope, facilitating an array of procedures both in the operating room and office settings. It is one of a few technologies that our team plans to launch to better serve the evolving patterns in Gynecology.” The HER izon Disposable Hysteroscope is a cutting-edge system that is introduced in alignment with ACOG and AAGL's advocacy for the elimination of blind assessment practices in the uterine cavity. Several key features of the HER izon Disposable Hysteroscope include. 1. Disposable Design: Single-use hysteroscope eliminates the need for traditional hysteroscope reprocessing, reduces the risk of cross-contamination, and ensures compliance with sterility standards. 2. Angled Cannula Tip: Provides rigidity to help enter the cervical canal and articulation to navigate an array of uterine cavity positions. 3. Compact Footprint: 4.8mm outer diameter sheath requires minimal or no dilation and 6Fr working channel allows for a broad spectrum of procedures such as direct visualization polypectomy, endometrial biopsy, D&C, and IUD removal. 4. User-Friendly Interface: High-Definition image technology, two LED lights provide bright and clear visualization, and the intuitive interface enables seamless system navigation. Dr. David Glassman, DO FACOG EMIGS, a prominent gynecologist in Phoenix, Arizona, shared his excitement about the new HER izon Disposable Hysteroscope, stating, “ HER izon is a revolutionary advancement in hysteroscopy technology. Designed with precision and patient comfort in mind, HER izon offers unparalleled clarity and control, providing healthcare professionals with a clearer view and easier access to the uterine cavity. Its innovative features enhance procedural efficiency, reducing both patient discomfort and procedure times. With HER izon, healthcare providers can elevate their practice, delivering superior care and empowering women to take control of their health with confidence.” The introduction of the HER izon Disposable Hysteroscope underscores Minerva Surgical’s commitment to providing gynecologists with solutions that improve patient outcomes. About Minerva Surgical, Inc. Minerva Surgical is a commercial-stage medical technology company focused on developing, manufacturing, distributing, and commercializing minimally invasive solutions to meet the distinct uterine healthcare needs of women. The Company has established a broad product line of commercially available, minimally invasive alternatives to hysterectomy, which are designed to address the most common causes of Abnormal Uterine Bleeding (AUB) in most uterine anatomies. The Minerva Surgical solutions can be used in a variety of medical treatment settings and aim to address the drawbacks associated with alternative treatment methods and to preserve the uterus by avoiding unnecessary hysterectomies. For more information about the HER izon Disposable Hysteroscope and other innovative medical devices from Minerva Surgical, please visit www.MinervaSurgical.com. The disposable hysteroscope is manufactured by Jiyuan Medical. Contact Details Minerva Surgical Kevin Tracey +1 855-646-7874 media@minervasurgical.com Company Website https://minervasurgical.com/

May 16, 2024 09:00 AM Eastern Daylight Time

Article thumbnail News Release

UNOS applauds passage of FAA reauthorization bill

United Network for Organ Sharing

Today, the United Network for Organ Sharing (UNOS) issued its support of Congress’ passage of the bipartisan, bicameral Federal Aviation Administration (FAA) reauthorization bill, which includes a provision to improve the safety and efficiency of the transportation of donor organs through the nation’s commercial aviation system. The bill now heads to the president’s desk for signature. The Securing Growth and Robust Leadership in American Aviation Act requires the Department of Transportation (DOT), in consultation with the FAA, to convene a working group to develop best practices for transporting organs in the cabin of a commercial aircraft. The working group will include organ procurement organizations, transplant hospitals, commercial airlines, flight attendants and other federal agencies. DOT is required to convene the working group no later than 90 days after the bill is enacted. No later than one year after convening, the working group must present recommendations to the secretary of DOT. Before the September 11 attacks, organs – primarily kidneys – were transported within a commercial flight’s main cabin under supervision of the aircrew. The attacks prompted significant changes to airport protocols, including removing transplant professionals’ ability to accompany an organ through security without an airplane ticket. As a result, organs currently travel in the cargo hold and are subject to cargo business hours, which vary between airlines and are impacted by staffing shortages. Organs arriving when a cargo office is closed sit on ice for prolonged periods, increasing the potential for an organ not to be used. “Ensuring a donated organ gets to a patient on time and safely is absolutely critical, which is why UNOS has been working with the donation and transplant community and Congress to create a process to bring organs out of the cargo hold and back into the cabin of an airplane,” said Maureen McBride, Ph.D., CEO of UNOS. “Thank you to those working with us to advocate for change and include this provision in the FAA reauthorization package, namely Senators Ron Wyden, Maria Cantwell, Ted Cruz, and John Thune, and Reps. Bruce Westerman, Greg Stanton, Beth Van Duyne, Sam Graves, and Rick Larsen. The bill’s passage highlights the bipartisan consensus and understanding of the lifesaving importance of this issue. I appreciate the commitment to honor the gift of life and do right by patients on the waitlist, generous donors, and their families. I look forward to working with the Department of Transportation to bring organs back into the cabin of an aircraft.” Transportation is a cornerstone of the UNOS Action Agenda, a series of recommendations to strengthen the U.S. donation and transplant system. To further reduce the risk of delaying or damaging organs in transport, UNOS also recommends the next contracts for the Organ Procurement and Transplantation Network (OPTN) should require the use of physical trackers for unaccompanied donor organs recovered for transplant, and the establishment of a centralized organ tracking system. “Donations and transplants are going up across the country, and so are the number of organs traveling every hour of every day,” said McBride. “This community owes it to patients and donor families to ensure that organs travel as safely and efficiently as possible. Every viable organ ultimately not transplanted represents a profound loss.” The provision included in the FAA reauthorization bill is the result of ongoing advocacy by UNOS and other members of the nation’s organ donation and transplant community. Since 2022, UNOS has engaged with FAA leadership, the Transportation Security Administration and the House and Senate to pursue this reform. Actions to move organs back to the airplane cabin and out of cargo are widely endorsed by the donation and transplant community, including the American Association of Kidney Patients, American Foundation for Donation & Transplantation, American Kidney Fund, American Society of Histocompatibility and Immunogenetics, American Society of Nephrology, American Society of Transplantation, American Society of Transplant Surgeons, Association of Organ Procurement Organizations, Donate Life America, Donate Life Virginia, Kidney Care Partners, Kidney Transplant Collaborative, National Kidney Foundation, Nationwide Organ Recovery Transport Alliance, North American Transplant Coordinators Organization, Organ Donation Advocacy Group, Renal Physicians Association, Transplant Recipients International Organization, Transplant Families, Transplant Unwrapped, and Waitlist Zero. About UNOS United Network for Organ Sharing (UNOS) is the mission-driven non-profit serving as the nation’s transplant system under contract with the federal government. We lead the network of transplant hospitals, organ procurement organizations, and thousands of volunteers who are dedicated to honoring the gifts of life entrusted to us and to making lifesaving transplants possible for patients in need. Working together, we leverage data and advances in science and technology to continuously strengthen the system, increase the number of organs recovered and the number of transplants performed, and ensure patients across the nation have equitable access to transplant. Contact Details United Network for Organ Sharing Anne Paschke +1 804-782-4730 anne.paschke@unos.org Company Website https://unos.org

May 15, 2024 02:53 PM Eastern Daylight Time

Article thumbnail News Release

FOR IMMEDIATE RELEASE

Apple Rush Company, Inc.

Apple Rush Company, Inc. (Otcpink:APRU), a leading player in the functional beverage industry, proudly announces it has cleared up final details of brand ownership with Bob Corr and Corr Brands, Inc. Tony Torgerud, CEO of Apple Rush, has negotiated a historical closing on the rights and trademarks of Corr Brands, Inc. In the transaction, Bob Corr has agreed to transfer the rights of the Corr Brands, Inc. trademarks and to forgo any royalties from previous agreements to give Tony and Apple Rush the best opportunity to succeed moving forward. Tony Torgerud said, “I have been negotiating for a year with Bob and he finally felt it was time to work out an agreement that would benefit everyone. Over the next couple months, all the required paperwork will be filed for transference and updates on all intellectual property held by Corr Brands, Inc. Not having to pay royalties will add thousands to the bottom line.” This agreement solidifies the future of the “Rush” family of brands that have been in the market since 1972. Bob Corr stated, “I want to see Apple Rush succeed and I feel the timing is right to get this deal done. I retired a long time ago and it is now time to write the next chapters of this story and with Apple Rush having its own production capabilities and its own tunnel pasteurizer, it is an opportunity that shouldn’t be wasted. I have given up hundreds of thousands of dollars in royalties, licensing fees and shares to enhance shareholder value.” With our pilot production abilities, we hope to do some reformulations to introduce a 2024 version of Ginseng Rush and the relaunch of the original Apple Rush flavor line. Apple Rush has held a license for 13 states and International distribution for the last 8 years and now owns the IP without paying the $5,000 per state license, another bottom line gain for all of our stockholders. About The Apple Rush Company, Inc. The Apple Rush Company, Inc., through its subsidiary APRU, LLC, is a distributor of CPG products under the trademarked Apple Rush brand, Element brand and other labels. The Apple Rush brand has more than 50 years of existence in the natural beverage industry. As a historical leader in the organic and natural beverage sector our goal is to now become a leader in the distribution of anhydrous hemp oil products nationwide. For more information, please go to www.aprubrands.com, www.element-brands.com, elementk.kratomwave.store www.alkhemicalroots.com with our expanded product portfolio. Safe Harbor Act: Forward-Looking Statements are included within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements regarding our expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations including words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and similar expressions are forward-looking statements and involve risks, uncertainties and contingencies, many of which are beyond our control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. We are under no obligation to (and expressly disclaim any such obligation to) update or alter forward-looking statements, whether as a result of new information, future events or otherwise. Contact Details Apple Rush Company, Inc. Tony Torgerud +1 888-741-3777 dtorgerud@aprullc.com Company Website http://www.aprubrands.com

May 14, 2024 10:00 AM Eastern Daylight Time

Article thumbnail News Release

PathAI Announces PLUTO: a State-of-the-art Foundation Model to Enhance AI-powered Pathology Tools

PathAI

PathAI, a global leader in AI-powered pathology, today announced the launch of Pathology Universal Transformer (PLUTO), a pathology-centric foundation model, to further differentiate their portfolio of products geared towards biopharma and pathology laboratory customers. In machine learning, a foundation model 1 (FM) is a model trained using self-supervised learning on a large scale of unlabeled data to mathematically capture salient information from inputs to the model. Once trained, the FM can be adapted to enable specific tasks in new contexts, especially including previously unforeseen contexts and tasks. The process of adapting a high-quality FM yields better downstream pathology tools, with lower development time and cost, than building bespoke tools from scratch. For example, a pathology FM may be adapted variously to perform cell and nucleus segmentation at microscopic scale on immunohistochemistry (IHC) slides, or to perform histological subtyping at macro-scale for H&E slides. Developing high-quality FMs is particularly important and complex in pathology where there are many different kinds of tasks at different scales of the whole slide image (WSI) data including cell, tissue, and (whole) slide levels. PathAI’s PLUTO was developed to enable this wide diversity of pathology tasks, and was trained using hundreds of millions of unlabeled image patches from about 160,000 WSIs across 30+ disease areas, numerous indications, stains, scanner types and magnification, and over 50 sources of data. To learn high-quality representations of the unlabeled training data, PathAI researchers designed a pathology-focused self-supervised training process using multi-scale, flexible deep vision transformer architectures with novel training objectives. Researchers then evaluated the quality of the resulting FM by adapting it to a wide diversity of pathology-specific tasks, and found that PathAI’s FM outperforms current state-of-the-art models on (whole) slide, cellular and subcellular tasks. Additionally, PathAI’s FM enables building AI-powered pathology tools at multiple scales and resolutions, and is significantly more compact than previously published models, driving massive reductions in training and inference costs, and enabling highly scalable data generation and product development. PLUTO and its adaptations are set to power PathAI’s best-in-class suite of AI products 2 for diagnostic pathology labs and biopharma use. PLUTO will be adapted to develop the next generation of PathAI’s best-in-class products. PLUTO’s embeddings will enable prediction of underlying molecular alterations driving cancer and disease phenotypes–including those previously hidden to AI–as well as the discovery of new biomarkers and therapeutic targets. “PLUTO is meticulously designed to fuel research efforts for better diagnostic and prognostic tools across multiple disease areas. This technology will enable users to compress their pathology workflows using an exceptionally diverse, multi-resolution foundation model at significantly greater speed and a much broader scale than before,” said Harsha Pokalla, Head of Machine Learning at PathAI. “Our aim is to deploy this single, robust model to address a diverse range of applications and use cases within pathology and to continue developing new high performance AI tools that serve our mission to improve patient outcomes.” Footnotes Foundation Models are for research use only. Not for use in diagnostic procedures. PathAI’s AI products are for research use only. Not for use in diagnostic procedures. About PathAI PathAI is the leading precision pathology company providing software and AI-enabled solutions to all pathologist stakeholders including laboratories, research institutions, and the biopharma industry. Rigorously trained and validated with data from more than 15 million annotations, its AI-powered models can be leveraged to optimize the analysis of pathology samples to improve efficiency and accuracy of pathology interpretation, as well as to better gauge therapeutic efficacy and accelerate drug development for complex diseases. For more information, please visit www.pathai.com. Contact Details SVM Public Relations and Marketing Communications Maggie Naples +1 401-490-9700 pathai@svmpr.com Company Website https://www.pathai.com/

May 14, 2024 10:00 AM Eastern Daylight Time

Article thumbnail News Release

College of American Pathologists: Cancer Rates Soaring in Younger Adults

YourUpdateTV

A video accompanying this announcement is available at: https://youtu.be/rq8XcHBnPw0 Cancer doesn’t discriminate by age today. Consider celebrities like Chadwick Boseman, who died from colon cancer; Olivia Munn, who recently underwent a double mastectomy; Ninja, a popular streamer on Twitch diagnosed with skin cancer; and Catherine, the Princess of Wales, who is currently being treated for the disease. All of them were diagnosed before the age of 50. Why is this happening and what can we do to catch it early? There are several reasons: diet, lifestyle, and environmental factors. The College of American Pathologists is emphasizing the importance of early detection, screening, and being vigilant regarding symptoms. A nationwide media tour was conducted to discuss this important issue featuring Dr. Donald Karcher, president of the College of American Pathologists. Topics that Dr. Karcher discussed included: · What is behind the soaring trend of younger adults being diagnosed with cancer? · What symptoms to look for to improve cancer outcomes. · What cancers can and should be screened for? · What if you don’t meet the minimum age requirements for screening but are having symptoms? · Discussing the importance of early detection. FOR MORE INFORMATION VISIT: YOURPATHOLOGIST.ORG Contact Details YourUpdateTV +1 212-736-2727 yourupdatetv@gmail.com

May 14, 2024 09:30 AM Eastern Daylight Time

Video
Article thumbnail News Release

NetScientific CEO hails deal with Martlet Capital as an important milestone

NetScientific PLC

NetScientific PLC (AIM:NSCI) CEO Dr Ilian Iliev takes Proactive's Stephen Gunnion through a transaction that will see NetScientific company EMV Capital become the investment advisor to Martlet Capital's portfolio of 53 investments while acquiring its operational venture capital business. Iliev said the transaction is part of NetScientific's strategic goal to become a leading deep tech and life sciences venture capital investor in the UK and Europe, employing a differentiated investment strategy characterised by proactive value creation and capital-light approaches. The deal notably expands NetScientific's assets under management by nearly doubling them with the addition of a £23 million portfolio from Marlet Capital and includes the acquisition of Martlet Capital’s operational team, forming a new entity under NetScientific. Iliev emphasised the alignment in ethos between NetScientific and Martlet Capital, rooted in long-term relationships and mutual commitment to the sectors. He also highlighted upcoming initiatives, including the launch of new funds aimed at investing in early-stage companies and growth opportunities within the UK, specifically in the Cambridge cluster. Contact Details Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com

May 13, 2024 10:55 AM Eastern Daylight Time

Video
Article thumbnail News Release

Lisata Therapeutics gets 2024 off to a strong start as it prepares for crucial ASCEND trial results

Lisata Therapeutics Inc

Lisata Therapeutics Inc (NASDAQ:LSTA) CEO David Mazzo tells Proactive's Stephen Gunnion that 2024 is a pivotal year for the oncology company, with Phase 2b ASCEND trial top-line data expected in the fourth quarter. Discussing the company's first-quarter milestones, Mazzo said the results are anticipated to be foundational for the company's future, potentially leading to provisional approval applications in Australia and subsequent discussions with the FDA and EMA. Mazzo highlighted Lisata's effective cash management, with over $43 million in funds ensuring operations into 2026. The company has achieved several regulatory milestones, including orphan designations for pancreatic cancer and glioma in the EU and US, and a rare pediatric disease designation for osteosarcoma in the US. Additionally, Mazzo discussed the rapid progress of the BOLSTER trial in cholangiocarcinoma, expected to provide early data points in 2025. The company plans to expand its trials and anticipates potential partnership announcements by year-end, driven by these developments. Contact Details Proactive North America +1 604-688-8158 NA-editorial@proactiveinvestors.com

May 13, 2024 10:45 AM Eastern Daylight Time

Video
1 ... 2223242526 ... 249